Theratechnologies Inc (TSE:TH) – Equities research analysts at National Bank Financial issued their Q3 2016 EPS estimates for shares of Theratechnologies in a research report issued to clients and investors on Wednesday. National Bank Financial analyst E. Leno expects that the brokerage will post earnings of $0.01 per share for the quarter. National Bank Financial also issued estimates for Theratechnologies’ Q4 2016 earnings at $0.01 EPS, FY2016 earnings at $0.01 EPS, FY2017 earnings at ($0.01) EPS and FY2018 earnings at ($0.02) EPS.
TH has been the subject of several other reports. Mackie reduced their price target on Theratechnologies from C$5.30 to C$4.40 in a research report on Wednesday, July 6th. Canaccord Genuity reduced their price target on Theratechnologies from C$4.25 to C$3.75 in a research report on Thursday, July 7th.
Shares of Theratechnologies (TSE:TH) opened at 2.95 on Monday. The firm has a market cap of $194.50 million and a price-to-earnings ratio of 268.18. Theratechnologies has a one year low of $1.26 and a one year high of $3.74. The stock’s 50 day moving average price is $2.63 and its 200 day moving average price is $2.44.
Theratechnologies Company Profile
Theratechnologies Inc is a Canada-based specialty pharmaceutical company. The Company addresses medical needs in metabolic disorders to promote healthy ageing among human immunodeficiency virus (HIV) patients. The Company’s product, EGRIFTA (tesamorelin for injection), is used for the reduction of excess abdominal fat in HIV-infected patients with lipodystrophy.
Receive News & Ratings for Theratechnologies Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Theratechnologies Inc and related companies with MarketBeat.com's FREE daily email newsletter.